Capstone Investment Advisors
ICPT

Capstone Investment Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Capstone Investment Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,919
Closed -$232K – 780
2017
Q2 		$232K Buy
1,919
+119
+7% +$13.8K 0.01% 533
2017
Q1 		$203K Buy
+1,800
New +$210K 0.01% 786
2015
Q4 		– Sell
-1,387
Closed -$230K – 569
2015
Q3 		$230K Buy
+1,387
New +$305K 0.01% 356

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Capstone Investment Advisors's ICPT Position: Q3 2017 in Review

Capstone Investment Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2017, closing a stake of 1,919 shares — an estimated $232K sold.

Capstone Investment Advisors first reported a position in ICPT in Q3 2015 and held it in 3 quarters. The position peaked at $232K in Q2 2017. 155 funds tracked by Wall St. Rank hold ICPT as of Q3 2017.

  • Capstone Investment Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Capstone Investment Advisors sold 1,919 Intercept Pharmaceuticals, Inc. shares in Q3 2017, an estimated $232K.
  • Capstone Investment Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2015 and held it in 3 quarters.
  • Capstone Investment Advisors's Intercept Pharmaceuticals, Inc. position peaked at $232K in Q2 2017.
  • 155 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2017.

Based on Capstone Investment Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.